Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.

ABSTRACT: The study is designed to analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with bevacizumab combined with FOLFOX or FOLFIRI regimen in a prospective cohort and to correlate this response with patient’s outcome.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Resecable Metastatic Cororectal Cancer.,Cancer

PROVIDER: 2145196 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors

Project description:To analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with cetuximab combined with FOLFOX or FOLFIRI regimen in a prospective cohort (RAS and B-RAF WT tumors) and to correlate this response with patient’s outcome.

| 2145197 | ecrin-mdr-crc

Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial).

Project description:Retrospective studies reported that preoperative oxaliplatin-based chemotherapy increased pathological response (PR) in patients resected for colorectal liver metastases (CRLM). This multicenter prospective randomized (1/1) phase II trial evaluated PR on resected CRLM after preoperative mFOLFOX6 (arm A) or FOLFIRI (arm B) + bevacizumab. The primary endpoint was the major pathological response rate (MPRR), defined as the percentage of patients presenting CRLMs with mean tumor regression grade (TRG) < 3. Secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). Out of 65 patients, 57 patients (28 and 29 in arm A/B) were resected for CRLM (one patient with lung metastases). Clinical and treatment characteristics were similar in both arms. One-month postoperative complications were 39.3%/31.0% in arm A/B (p = 0.585). MPRR and complete PR were 32.1%/20.7% (p = 0.379) and 14.3%/0.0% (p = 0.052) in arm A/B, respectively. PFS and OS were not different. Patients with PR among all CRLMs (max TRG ≤ 3; 43.8% of patients) had a lower risk of relapse (PFS: HR = 0.41, 95%CI = 0.204-0.840, p = 0.015) and a tendency towards better survival (OS: HR = 0.34, 95%CI = 0.104-1.114, p = 0.075). The homogeneity of PR was associated with improved PFS/OS. This trial fails to demonstrate a significant increase in MPRR in patients treated with mFOLFOX6-bevacizumab but confirms PR as an important prognostic factor.

| S-EPMC8909786 | biostudies-literature

Ago iCLIP of TLE patient resected hippocampus

Project description:Nine patients with temporal lobe epilepsy (TLE) underwent hippocampal resection. Six had hippocampal sclerosis, three did not show signs of hippocampal sclerosis. Resected hippocampi were used for Ago iCLIP to detect miRNA targeting in the resected tissue.

2023-06-02 | GSE214317 | GEO

Ago iCLIP of TLE patient resected hippocampus

Project description:Ago iCLIP of TLE patient resected hippocampus

| PRJNA884734 | ENA

Phase II Clinical and Immune Correlate Study of Adjuvant Nivolumab plus Ipilimumab for High-Risk Resected Melanoma

Project description:Phase II Clinical and Immune Correlate Study of Adjuvant Nivolumab plus Ipilimumab for High-Risk Resected Melanoma

| PRJNA907804 | ENA

mRNA sequencing of primary tumors resected from mice

Project description:mRNA sequencing of primary tumors resected from mice

| PRJNA821495 | ENA

mRNA sequencing of primary tumors resected from mice

Project description:Mice were injected with MDAMB231 cells (weakly adherent, strongly adherent, or unsorted control) that were allowed to grow into a tumor for 6 weeks. After 6 weeks, the mice were sacrificed and the tumors were resected. mRNA sequencing was performed on dissociated cells from the tumors.

2022-09-01 | GSE199785 | GEO

Ager (Rage) and Myd88 deletion in resected mouse livers

Project description:The effect of resection of mouse livers on survival serve as a model for the effect of resection of human livers, which are performed for both the purposes of removing sick tissue and for transplanting healthy tissue. When less than 70% of a mouse liver is resected, the mouse usually lives. However, when more than 70% is resected, there is an increased probability that the mouse will die. We have found that deletion of Ager (Advanced Glycation End products receptor) (Rage) increases the chance of mouse survival relavtive to WT. Conversely, the deletion of Myd88 decreases the chances of survival, as does the simultaneous deletion of both Ager and Myd88. To understand these genotype/phenotype relations, we performed gene expression measurements.

2012-06-26 | GSE22873 | GEO

mRNA sequencing analysis of fresh resected lung tissues from tuberculosis patients

Project description:Fresh resected lung tissues were obtained from nine tuberculosis patients with elevated pulmonary 18F-FDG avidity. Lung tissues with 18F-FDG avidity and nearby uninvolved tissues were profiled with mRNA sequencing.

2025-04-09 | GSE277481 | GEO

miRNA sequencing analysis of fresh resected lung tissues from tuberculosis patients

2025-04-09 | GSE276819 | GEO